Eli Lilly and Company (NYSE:LLY) Shares Acquired by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 19.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,354 shares of the company’s stock after acquiring an additional 6,386 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Eli Lilly and Company were worth $30,381,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Essex LLC lifted its holdings in Eli Lilly and Company by 1.5% in the 4th quarter. Essex LLC now owns 1,980 shares of the company’s stock worth $1,529,000 after buying an additional 30 shares in the last quarter. Quotient Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 4.8% in the 4th quarter. Quotient Wealth Partners LLC now owns 3,154 shares of the company’s stock worth $2,435,000 after buying an additional 145 shares in the last quarter. Northeast Investment Management lifted its holdings in Eli Lilly and Company by 4.3% in the 4th quarter. Northeast Investment Management now owns 53,478 shares of the company’s stock worth $41,285,000 after buying an additional 2,226 shares in the last quarter. Summit Wealth & Retirement Planning Inc. lifted its holdings in Eli Lilly and Company by 84.5% in the 4th quarter. Summit Wealth & Retirement Planning Inc. now owns 546 shares of the company’s stock worth $422,000 after buying an additional 250 shares in the last quarter. Finally, Investment Advisory Services Inc. TX ADV lifted its holdings in Eli Lilly and Company by 8.1% in the 4th quarter. Investment Advisory Services Inc. TX ADV now owns 322 shares of the company’s stock worth $248,000 after buying an additional 24 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $868.57 on Tuesday. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $824.55 billion, a price-to-earnings ratio of 74.17, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. The company has a 50-day moving average price of $789.87 and a two-hundred day moving average price of $843.19.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. Analysts forecast that Eli Lilly and Company will post 23.33 EPS for the current year.

Eli Lilly and Company declared that its board has approved a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a $1.50 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s dividend payout ratio is 44.41%.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Citigroup cut their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Wells Fargo & Company cut their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.